This study strengthens the available evidence that mRNA expression of EMP1, CASP1, and NLRP3 may serve as potential biomarkers for risk stratification of pediatric B-ALL patients. This evidence concerns the gene EMP1 and precursor B-cell acute lymphoblastic leukemia.